Skip to main content
Clinical Trials/JPRN-jRCTs051210002
JPRN-jRCTs051210002
Recruiting
Phase 2

Examination of the adverse event occurrence suppression effect by K15 lactic acid bacteria intake during preoperative chemotherapy for esophageal cancer - K15 lactic acid bacteria for esophageal cancer

Miyata Hiroshi0 sites50 target enrollmentApril 5, 2021

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Esophageal cancer
Sponsor
Miyata Hiroshi
Enrollment
50
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 5, 2021
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Miyata Hiroshi

Eligibility Criteria

Inclusion Criteria

  • (1\) Endoscopic biopsy confirmed histologically to be esophageal cancer (regardless of tissue type).
  • (2\) Patients with resectable esophageal cancer that does not show metastases to other organs by pre\-treatment imaging and who are scheduled to undergo radical surgery for esophageal cancer after preoperative chemotherapy.
  • (3\) Dysphagia score 0\-2
  • (4\) Age: 20 to 80 years old
  • (5\) ECOG Performance status: 0\-1
  • (6\) Patients whose functions of major organs (bone marrow, heart, lungs, kidneys, etc.) are well preserved.
  • (7\) Cases where written consent was obtained from the patient
  • (8\) It can be judged that esophagectomy can be performed by thoracotomy (or thoracoscopic) laparotomy (or laparoscopic).

Exclusion Criteria

  • (1\) Active double cancer (excluding double cancer that can be cured by local treatment)
  • (2\) Cases with a history of irradiation for head and neck cancer
  • (3\) Cases with severe absorption disorders
  • (4\) Patients with severe passage obstruction who require central parenteral nutrition or nutritional support with nasogastric tube during registration
  • (5\) Cases in which the dose of the initial preoperative chemotherapy needs to be reduced due to decreased organ function or failure
  • (6\) Cases of inflammatory bowel disease
  • (7\) Patients with poor glycemic control during treatment (HbA1c\>8\.0%)
  • (8\) Cases with milk protein allergy
  • (9\) Cases with a history of gastrointestinal resection
  • (10\) Cases that the investigator considers inappropriate

Outcomes

Primary Outcomes

Not specified

Similar Trials